Purpose/ObjectiveCurrent radiotherapy (RT) planning workflows rely on pre-treatment simulation CT (sCT), which can significantly delay treatment initiation, particularly in resource-constrained settings. While diagnostic CT (dCT) offers a potential alternative for expedited planning, inherent geometric discrepancies from sCT in patient positioning and table curvature limit its direct use for accurate RT planning. This study presents a novel AI-based method designed to overcome these limitations by generating synthetic simulation CT (ssCT) directly from standard dCT for spinal palliative RT, aiming to eliminate the need for sCT and accelerate the treatment workflow. Materials/MethodsssCTs were generated using two neural network models to adjust spine position and correct table curvature. The neural networks use a three-layer structure (ReLU activation), optimized by Adam with MSE loss and MAE metrics. The models were trained on paired dCT and sCT images from 30 patients undergoing palliative spine radiotherapy from a safety-net hospital, with 22 cases used for training and 8 for testing. To explore institutional dependence, the models were also tested on 7 patients from an academic medical center (AMC). To evaluate ssCT accuracy, both ssCT and dCT were aligned with sCT using the same frame of reference rigid registration on bone windows. Dosimetric differences were assessed by comparing dCT vs. sCT and ssCT vs. sCT, quantifying deviations in dose-volume histogram (DVH) metrics, including Dmean, Dmax, D95, D99, V100, V107, and root-mean-square (RMS) differences. The imaging and plan quality was assessed by four radiation oncologists using a Likert score. The Wilcoxon signed-rank test was used to determine whether there is a significant difference between the two methods. ResultsFor the safety-net hospital cases, the generated ssCT demonstrated significantly improved geometric and dosimetric accuracy compared to dCT. ssCT reduced the mean difference in key dosimetric parameters (e.g., Dmean difference decreased from 2.0% for dCT vs. sCT to 0.57% for ssCT vs. sCT with significant improvement under the Wilcoxon signed-rank test) and achieved a significant reduction in the RMS difference of DVH curves (from 6.4% to 2.2%). Furthermore, physician evaluations showed that ssCT was consistently rated as significantly superior for treatment planning images (mean scores improving from "Acceptable" for dCT to "Good to Perfect" for ssCT), reflecting improved confidence in target and tissue positioning. In the academic medical-center cohort--where technologists already apply meticulous pre-scan alignment--ssCT still yielded statistically significant, though smaller, improvements in several dosimetric endpoints and in observer ratings. ConclusionOur AI-driven approach successfully generates ssCT from dCT that achieves geometric and dosimetric accuracy comparable to sCT for spinal palliative RT planning. By specifically addressing critical discrepancies like spine position and table curvature, this method offers a robust approach to bypass the need for dedicated sCT simulations. This advancement has the potential to significantly streamline the RT workflow, reduce treatment uncertainties, and accelerate time to treatment, offering a highly promising solution for improving access to timely and accurate radiotherapy, especially in limited-resource environments.

BackgroundCarotid plaque presence is associated with cardiovascular risk, even among asymptomatic individuals. While deep learning has shown promise for carotid plaque phenotyping in patients with advanced atherosclerosis, its application in population-based settings of asymptomatic individuals remains unexplored. MethodsWe developed a YOLOv8-based model for plaque detection using carotid ultrasound images from 19,499 participants of the population-based UK Biobank (UKB) and fine-tuned it for external validation in the BiDirect study (N = 2,105). Cox regression was used to estimate the impact of plaque presence and count on major cardiovascular events. To explore the genetic architecture of carotid atherosclerosis, we conducted a genome-wide association study (GWAS) meta-analysis of the UKB and CHARGE cohorts. Mendelian randomization (MR) assessed the effect of genetic predisposition to vascular risk factors on carotid atherosclerosis. ResultsOur model demonstrated high performance with accuracy, sensitivity, and specificity exceeding 85%, enabling identification of carotid plaques in 45% of the UKB population (aged 47-83 years). In the external BiDirect cohort, a fine-tuned model achieved 86% accuracy, 78% sensitivity, and 90% specificity. Plaque presence and count were associated with risk of major adverse cardiovascular events (MACE) over a follow-up of up to seven years, improving risk reclassification beyond the Pooled Cohort Equations. A GWAS meta-analysis of carotid plaques uncovered two novel genomic loci, with downstream analyses implicating targets of investigational drugs in advanced clinical development. Observational and MR analyses showed associations between smoking, LDL cholesterol, hypertension, and odds of carotid atherosclerosis. ConclusionsOur model offers a scalable solution for early carotid plaque detection, potentially enabling automated screening in asymptomatic individuals and improving plaque phenotyping in population-based cohorts. This approach could advance large-scale atherosclerosis research. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=131 SRC="FIGDIR/small/24315675v2_ufig1.gif" ALT="Figure 1"> View larger version (33K): [email protected]@27a04corg.highwire.dtl.DTLVardef@18cef18org.highwire.dtl.DTLVardef@1a53d8f_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGRAPHICAL ABSTRACT.C_FLOATNO ASCVD - Atherosclerotic Cardiovascular Disease, CVD - Cardiovascular disease, PCE - Pooled Cohort Equations, TP- true positive, FN - False Negative, FP - False Positive, TN - True Negative, GWAS - Genome-Wide Association Study. C_FIG CLINICAL PERSPECTIVECarotid ultrasound is a well-established method for assessing subclinical atherosclerosis with potential to improve cardiovascular risk assessment in asymptomatic individuals. Deep learning could automate plaque screening and enable processing of large imaging datasets, reducing the need for manual annotation. Integrating such large-scale carotid ultrasound datasets with clinical, genetic, and other relevant data can advance cardiovascular research. Prior studies applying deep learning to carotid ultrasound have focused on technical tasks-plaque classification, segmentation, and characterization-in small sample sizes of patients with advanced atherosclerosis. However, they did not assess the potential of deep learning in detecting plaques in asymptomatic individuals at the population level. We developed an efficient deep learning model for the automated detection and quantification of early carotid plaques in ultrasound imaging, primarily in asymptomatic individuals. The model demonstrated high accuracy and external validity across population-based cohort studies. Predicted plaque prevalence aligned with known cardiovascular risk factors. Importantly, predicted plaque presence and count were associated with future cardiovascular events and improved reclassification of asymptomatic individuals into clinically meaningful risk categories. Integrating our model predictions with genetic data identified two novel loci associated with carotid plaque presence--both previously linked to cardiovascular disease--highlighting the models potential for population-scale atherosclerosis research. Our model provides a scalable solution for automated carotid plaque phenotyping in ultrasound images at the population level. These findings support its use for automated screening in asymptomatic individuals and for streamlining plaque phenotyping in large cohorts, thereby advancing research on subclinical atherosclerosis in the general population.

Coronary microvascular disease (CMVD) is an underdiagnosed but significant contributor to the burden of ischemic heart disease, characterized by angina and myocardial infarction. The development of risk prediction models such as polygenic risk scores (PRS) for CMVD has been limited by a lack of large-scale genome-wide association studies (GWAS). However, there is significant overlap between CMVD and enrollment criteria for coronary artery disease (CAD) GWAS. In this study, we developed CMVD PRS models by selecting variants identified in a CMVD GWAS and applying weights from an external CAD GWAS, using CMVD-associated loci as proxies for the genetic risk. We integrated plasma proteomics, clinical measures from perfusion PET imaging, and PRS to evaluate their contributions to CMVD risk prediction in comprehensive machine and deep learning models. We then developed a novel unsupervised endotyping framework for CMVD from perfusion PET-derived myocardial blood flow data, revealing distinct patient subgroups beyond traditional case-control definitions. This imaging-based stratification substantially improved classification performance alongside plasma proteomics and PRS, achieving AUROCs between 0.65 and 0.73 per class, significantly outperforming binary classifiers and existing clinical models, highlighting the potential of this stratification approach to enable more precise and personalized diagnosis by capturing the underlying heterogeneity of CMVD. This work represents the first application of imaging-based endotyping and the integration of genetic and proteomic data for CMVD risk prediction, establishing a framework for multimodal modeling in complex diseases.

BackgroundMyocarditis is a life-threatening disease with significant hemodynamic risks during the acute phase. Although histopathological examination of myocardial biopsy specimens remains the gold standard for diagnosis, there is no established method for objectively quantifying cardiomyocyte damage. We aimed to develop an AI model to evaluate clinical myocarditis severity using comprehensive pathology data. MethodsWe retrospectively analyzed 314 patients (1076 samples) who underwent myocardial biopsy from 2002 to 2021 at the National Cerebrovascular Center. Among these patients, 158 were diagnosed with myocarditis based on the Dallas criteria. A Multiple Instance Learning (MIL) model served as a pre-trained classifier to detect myocarditis across whole-slide images. We then constructed two clinical severity-prediction models: (1) a logistic regression model (Model 1) using the density of inflammatory cells per unit area, and (2) a Transformer-based model (Model 2), which processed the top-ranked patches identified by the MIL model to predict clinical severe outcomes. ResultsModel 1 achieved an AUROC of 0.809, indicating a robust association between inflammatory cell density and severe myocarditis. In contrast, Model 2, the Transformer-based approach, yielded an AUROC of 0.993 and demonstrated higher accuracy and precision for severity prediction. Attention score visualizations showed that Model 2 captured both inflammatory cell infiltration and additional morphological features. These findings suggest that combining MIL with Transformer architectures enables more comprehensive identification of key histological markers associated with clinical severe disease. ConclusionsOur results highlight that a Transformer-based AI model analyzing whole-slide pathology images can accurately assess clinical myocarditis severity. Moreover, simply quantifying the extent of inflammatory cell infiltration also correlates strongly with clinical outcomes. These methods offer a promising avenue for improving diagnostic precision, guiding treatment decisions, and ultimately enhancing patient management. Future prospective studies are warranted to validate these models in broader clinical settings and facilitate their integration into routine pathological workflows. What is new?- This is the first study to apply an AI model for the diagnosis and severity assessment of myocarditis. - New evidence shows that inflammatory cell infiltration is related to the severity of myocarditis. - Using information from the entire tissue, not just inflammatory cells, allows for a more accurate assessment of myocarditis severity. What are the clinical implications?- The use of the AI model allows for an unprecedented histological evaluation of myocarditis severity, which can enhance early diagnosis and intervention strategies. - Rapid and precise assessments of myocarditis severity by the AI model can support clinicians in making timely and appropriate treatment decisions, potentially improving patient outcomes. - The incorporation of this AI model into clinical practice may streamline diagnostic workflows and optimize the allocation of medical resources, enhancing overall patient care.

Lung neuroendocrine tumours (NETs, also known as carcinoids) are rapidly rising in incidence worldwide but have unknown aetiology and limited therapeutic options beyond surgery. We conducted multi-omic analyses on over 300 lung NETs including whole-genome sequencing (WGS), transcriptome profiling, methylation arrays, spatial RNA sequencing, and spatial proteomics. The integration of multi-omic data provides definitive proof of the existence of four strikingly different molecular groups that vary in patient characteristics, genomic and transcriptomic profiles, microenvironment, and morphology, as much as distinct diseases. Among these, we identify a new molecular group, enriched for highly aggressive supra-carcinoids, that displays an immune-rich microenvironment linked to tumour--macrophage crosstalk, and we uncover an undifferentiated cell population within supra-carcinoids, explaining their molecular and behavioural link to high-grade lung neuroendocrine carcinomas. Deep learning models accurately identified the Ca A1, Ca A2, and Ca B groups based on morphology alone, outperforming current histological criteria. The characteristic tumour microenvironment of supra-carcinoids and the validation of a panel of immunohistochemistry markers for the other three molecular groups demonstrates that these groups can be accurately identified based solely on morphological features, facilitating their implementation in the clinical setting. Our proposed morpho-molecular classification highlights group-specific therapeutic opportunities, including DLL3, FGFR, TERT, and BRAF inhibitors. Overall, our findings unify previously proposed molecular classifications and refine the lung cancer map by revealing novel tumour types and potential treatments, with significant implications for prognosis and treatment decision-making.

Fetal MRI is increasingly being employed in the diagnosis of fetal lung anomalies and segmentation-derived total fetal lung volumes are used as one of the parameters for prediction of neonatal outcomes. However, in clinical practice, segmentation is performed manually in 2D motion-corrupted stacks with thick slices which is time consuming and can lead to variations in estimated volumes. Furthermore, there is a known lack of consensus regarding a universal lung parcellation protocol and expected normal total lung volume formulas. The lungs are also segmented as one label without parcellation into lobes. In terms of automation, to the best of our knowledge, there have been no reported works on multi-lobe segmentation for fetal lung MRI. This work introduces the first automated deep learning segmentation pipeline for multi-regional lung segmentation for 3D motion-corrected T2w fetal body images for normal anatomy and congenital diaphragmatic hernia cases. The protocol for parcellation into 5 standard lobes was defined in the population-averaged 3D atlas. It was then used to generate a multi-label training dataset including 104 normal anatomy controls and 45 congenital diaphragmatic hernia cases from 0.55T, 1.5T and 3T acquisition protocols. The performance of 3D Attention UNet network was evaluated on 18 cases and showed good results for normal lung anatomy with expectedly lower Dice values for the ipsilateral lung. In addition, we also produced normal lung volumetry growth charts from 290 0.55T and 3T controls. This is the first step towards automated multi-regional fetal lung analysis for 3D fetal MRI.

Precise aneurysm volume measurement offers a transformative edge for risk assessment and treatment planning in clinical settings. Currently, clinical assessments rely heavily on manual review of medical imaging, a process that is time-consuming and prone to inter-observer variability. The widely accepted standard-of-care primarily focuses on measuring aneurysm diameter at its widest point, providing a limited perspective on aneurysm morphology and lacking efficient methods to measure aneurysm volumes. Yet, volume measurement can offer deeper insight into aneurysm progression and severity. In this study, we propose an automated approach that leverages the strengths of pre-trained neural networks and expert systems to delineate aneurysm boundaries and compute volumes on an unannotated dataset from 60 patients. The dataset includes slice-level start/end annotations for aneurysm but no pixel-wise aorta segmentations. Our method utilizes a pre-trained UNet to automatically locate the aorta, employs SAM2 to track the aorta through vascular irregularities such as aneurysms down to the iliac bifurcation, and finally uses a Long Short-Term Memory (LSTM) network or expert system to identify the beginning and end points of the aneurysm within the aorta. Despite no manual aorta segmentation, our approach achieves promising accuracy, predicting the aneurysm start point with an R2 score of 71%, the end point with an R2 score of 76%, and the volume with an R2 score of 92%. This technique has the potential to facilitate large-scale aneurysm analysis and improve clinical decision-making by reducing dependence on annotated datasets.

IntroductionIntegrated digital diagnostics can support complex surgeries in many anatomic sites, and brain tumour surgery represents one of the most complex cases. Neurosurgeons face several challenges during brain tumour surgeries, such as differentiating critical tissue from brain tumour margins. To overcome these challenges, the STRATUM project will develop a 3D decision support tool for brain surgery guidance and diagnostics based on multimodal data processing, including hyperspectral imaging, integrated as a point-of-care computing tool in neurosurgical workflows. This paper reports the protocol for the development and technical validation of the STRATUM tool. Methods and analysisThis international multicentre, prospective, open, observational cohort study, STRATUM-OS (study: 28 months, pre-recruitment: 2 months, recruitment: 20 months, follow-up: 6 months), with no control group, will collect data from 320 patients undergoing standard neurosurgical procedures to: (1) develop and technically validate the STRATUM tool, and (2) collect the outcome measures for comparing the standard procedure versus the standard procedure plus the use of the STRATUM tool during surgery in a subsequent historically controlled non-randomized clinical trial. Ethics and disseminationThe protocol was approved by the participant Ethics Committees. Results will be disseminated in scientific conferences and peer-reviewed journals. Trial registration number[Pending Number] ARTICLE SUMMARYO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LISTRATUM-OS will be the first multicentre prospective observational study to develop and technically validate a 3D decision support tool for brain surgery guidance and diagnostics in real-time based on artificial intelligence and multimodal data processing, including the emerging hyperspectral imaging modality. C_LIO_LIThis study encompasses a prospective collection of multimodal pre, intra and postoperative medical data, including innovative imaging modalities, from patients with intra-axial brain tumours. C_LIO_LIThis large observational study will act as historical control in a subsequent clinical trial to evaluate a fully-working prototype. C_LIO_LIAlthough the estimated sample size is deemed adequate for the purpose of the study, the complexity of the clinical context and the type of surgery could potentially lead to under-recruitment and under-representation of less prevalent tumour types. C_LI

A diagnostic medical foundation model (MedFM) is an artificial intelligence (AI) system engineered to accurately determine diagnoses across various medical imaging modalities and specialties. To train MedFM, we created the PubMed Central Medical Images Dataset (PMCMID), the largest annotated medical image dataset to date, comprising 16,126,659 images from 3,021,780 medical publications. Using AI- and ontology-based methods, we identified 4,482,237 medical images (e.g., clinical photos, X-rays, ultrasounds) and generated comprehensive annotations. To optimize MedFMs performance and assess biases, 13,266 images were manually annotated to establish a multimodal benchmark. MedFM achieved physician-level performance in diagnosis tasks spanning radiology, dermatology, and infectious diseases without requiring specific training. Additionally, we developed the Image2Paper app, allowing clinicians to upload medical images and retrieve relevant literature. The correct diagnoses appeared within the top ten results in 88.4% and at least one relevant differential diagnosis in 93.0%. MedFM and PMCMID were made publicly available. FundingResearch reported here was partially supported by the National Cancer Institute (NCI) (R01 CA260271), the Saudi Company for Artificial Intelligence (SCAI) Authority, and the German Federal Ministry for Economic Affairs and Climate Action (BMWK) under the project DAKI-FWS (01MK21009E). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.